Telomir Pharmaceuticals (NASDAQ: TELO) has announced groundbreaking preclinical findings suggesting that its licensed molecule, Telomir-1, can reverse key Type 2 diabetes parameters. As a leader in age-reversal science, Telomir Pharmaceuticals’ findings highlight the molecule’s potential to transform diabetes management by directly addressing the issue of insulin resistance.
Type 2 Diabetes and Telomir-1
Type 2 diabetes is caused when the body becomes resistant to insulin, resulting in glucose no longer effectively entering the cells to be used for energy. The pancreas overcompensates insulin production, elevating blood sugar levels. Type 2 diabetes affects over 800 million people worldwide and costs $966 billion annually.Â
The study carried out by Telomir Pharmaceuticals, conducted in collaboration with India-based Pentagrit, hoped to use the Telomir-1 molecule to reverse Type 2 diabetes induced by high-calorie diets.
Results of the Experiment
The experiment involved zebrafish, commonly used as model organisms since the 1960s, to understand the development of diseases, including cancer. These zebrafish models experienced Type 2 diabetes induced by high-calorie diets and produced these key results:
- Reversal of Hyperglycemia and Insulin Resistance: As observed in the experiment, the Telomir-1 molecule normalized blood glucose and insulin levels in a dose-dependent manner, restoring natural glucose homeostasis.
- Improved Insulin Sensitivity: Researchers observed significant reductions in their Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values during the experiment. While insulin sensitivity was not completely restored, near pre-diabetic sensitivity levels were observed.
- Enhanced Glucose Clearance: When Oral Glucose Tolerance Tests (OGTTs) were performed on the zebrafish models, results showed improved glucose metabolism.
- Increased Survival Rates: Zebrafish models treated with the Telomir-1 molecule demonstrated improved survival rates compared to the control groups.
How Telomir-1 Works
Telomir-1 works by addressing iron homeostasis since excess iron levels are known to exacerbate insulin resistance. By targeting systemic iron metabolism, which reduces insulin resistance, oxidative stress, and beta-cell damage, Telomir-1 manages iron levels to address the underlying issues of Type 2 diabetes.
“Telomir-1’s unique approach to insulin resistance marks a paradigm shift in chronic disease treatment,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir.
Broader Implications
The success of the Telomir-1 molecule reflects Telomir Pharmaceuticals’ greater vision to target the root causes of chronic diseases. This study builds on Telomir-1’s exciting potential to reverse aging processes and improve health.
CEO Erez Aminov said, “We’ve observed Telomir-1’s ability to reverse key diabetes parameters while also enhancing survival. These results reinforce its potential to transform age-related disease management.”
Future Direction for Telomir-1
Moving forward, Telomir Pharmaceuticals plans to expand its research by exploring Telomir-1’s potential applications regarding the following conditions:
- Progeria: Telomir-1 may affect accelerated aging.
- Alzheimer’s Disease: Telomir-1 may have the potential to reduce neurodegeneration.
- Osteoarthritis and Inflammatory Diseases: Telomir-1 may impact joint health and reduce inflammation.
- Cancer Models: Telomir Pharmaceuticals is exploring applications of Telomir-1 on oncological conditions.
As it stands, Telomir-1 has remarkable potential to address the core issues of chronic diseases. Already demonstrating progress with Type 2 diabetes management, Telomir Pharmaceuticals’ groundbreaking work will continue addressing age-related and metabolic diseases.
